The ALARION-EV trial will evaluate AtaCor Medical’s investigational parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to provide an alternative approach to traditional ICD therapy for patients at risk of life-threatening arrhythmias.
